## Press release

# New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

**Stockholm, Sweden, June 30, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12–15, including data on its subcutaneous formulation, long-term use across diverse patient groups, maintenance dosing, and at-home administration.**

BioArctic will also participate in the Plenary Session *"Prevalence of Alzheimer's Disease Pathology in the Community,"* taking place on 14 July (11:00am to 12:15pm BST). In a presentation called *"Outcomes of Clinical Progression for Clinical Trials of People with Neuronal Synucleinopathy with Cognitive Impairment",* strategies for assessing clinical progression in people with cognitive impairment related to α-synuclein pathology will be discussed, primarily across Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB).

**Key oral lecanemab presentations at AAIC**

- **Subcutaneous treatment data**: On Sunday, July 12, as part of the "*Developing Topics Session: Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations"* (4:15-5:45pm BST), emerging clinical evidence and practical use considerations for the subcutaneous formulation of lecanemab will be presented, including clinical trial and real-world patient experience.

- **LEADER study – real-world evidence from US clinical practice:** On Tuesday, July 14, as part of the *"Featured Research Session: Lecanemab Three Years Post Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings"* (4:15-5:45pm BST), data from the LEADER study evaluating real-world lecanemab use in diverse US clinical settings three years post-approval, will be presented. It will include results on maintenance dosing with IV treatment every four weeks and the first reported findings of at-home subcutaneous administration.

- **Preclinical Alzheimer's disease:** Presentations on the Phase 3 AHEAD 3-45 study in preclinical Alzheimer's Disease will highlight progress of the trial, including updates on participant retention and engagement.

**Additional oral presentations**

| Presentation date and time (BST) | Presentation title and abstract number |
|---|---|
| July 12<br>2:00 – 3:30pm | *Developing Topics Session 1-23-FRSB Developing Topics in Amyloid Targeting Therapies: Global Perspectives from Trials to Real World Evidence.* |

| | |
|---|---|
| | Presentation: *Treatment Actions following ARIA in Patients Treated with Lecanemab: Evidence from a Post-Marketing Observational Study in Japan* (Abstract ID TBA) |
| July 13<br>8:00 – 8:45am | *Developing Topic Session #2-6-DEV: Developing Topics in Amyloid Targeting Therapies and Real-World Outcomes.*<br><br>Presentation: *Sex-Based Outcomes of Lecanemab in Early Alzheimer's Disease: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER)* (Abstract ID TBA) |
| July 13<br>9:00 – 10:30am | *Featured Research Session #2-15-FRS-A: External Controls In Alzheimer's Clinical Trials: How Far Away Are We?*<br><br>Presentation: *External Controls in Open-Label Extensions: Insights from Clarity AD* (Abstract ID 982) |
| July 14<br>8:00 – 8:45am | *Developing Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's Disease.*<br><br>Presentation: *Broad Modulation of Core Tau Biomarkers, Including pTau205 Following Lecanemab Treatment* (Abstract ID 13515) |
| July 14<br>8:00 – 8:45am | *Developing Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's Disease.*<br><br>Presentation: *Tau PET Change in CLARITY-AD* (Abstract ID 13333) |
| July 14<br>8:00 – 8 :45am | *Developing Topics Session #3-3-DEV: Developing Topics in Factors Affecting Fluid Biomarkers.*<br><br>Presentation: *Racial And Ethnic Differences in %p-tau217 Associations with Cognitive Performance and Amyloid PET In Preclinical AD* (Abstract ID 13712) |
| July 14<br>9:00 – 10:30am | *Featured Research Session #3-15-FRS-A: Anti-Amyloid Therapy: Real World Experience.*<br><br>Presentation: *Lecanemab Clinical Practice: A Multicenter, Surveillance Safety Study from the ALZ-NET Registry* (Abstract ID 6202) |

**Poster presentations on lecanemab**

*Poster viewing time is set from 7:30am – 4:15pm BST on the date of presentation*

| Presentation date | Presentation title and abstract number |
|---|---|
| July 12 | *Characterization and Utilization Assessment of a Centrally Supported Ride-Share Service Implemented in a Multisite Preclinical Alzheimer's Clinical Trial* (Abstract ID TBA) |
| | *Long-Term Persistence and Patient Characteristics for Intravenous and Subcutaneous Lecanemab in Real-World Use in the United States* (Abstract ID 7344) |
| | *Retrospective Case Series of Real-world Clinical and Patient-reported Outcomes with Lecanemab* (Abstract ID 9480) |
| | *Retrospective Observational Cohort Study of Real-world Clinical and Patient-reported Outcomes with Lecanemab* (Abstract ID 9882) |

| | |
|---|---|
| July 13 | *Subcutaneous Lecanemab Administration in an Alzheimer's Disease Treatment Center: Real-World Clinical Outcomes and Patient Experiences* (Abstract ID 1556) |
| | *INITIATE-SC: A Multicenter Real-World Study of Subcutaneous Lecanemab Initiation in Early Alzheimer's Disease* (Abstract ID 13568) |
| | *Continued or Time-limited Treatment Benefits of Anti-amyloid Monoclonal Antibodies In Early Alzheimer's Disease* (Abstract ID 13738) |
| | *Early Alzheimer's Disease Treated with Lecanemab: A Real-World, Retrospective Analysis from a Colorado Neurological Clinic* (Abstract ID 12904) |
| | *Communicating Participant Milestones to Enhance Trial Engagement and Retention in a Preclinical Alzheimer's Trial* (Abstract ID 9159) |
| | *Initial Real-World Experience in Using Lecanemab in Hong Kong: Safety and Preliminary PET CT Data* (Abstract ID 11962) |
| July 14 | *Real-World Lecanemab Treatment in Early Alzheimer's Disease: A Retrospective Dementia Clinic Case Series Review from a Geriatric Medicine Clinical Practice* (Abstract ID 1947) |
| July 15 | *A Time and Motion and Patient Satisfaction Study of Subcutaneous Injection of Lecanemab for Patients with Early Alzheimer's Disease* (Abstract ID 13637) |
| | *Differential Costs Of Amyloid-related Imaging Abnormality Management Between Anti-amyloid Treatments: Estimates Based On A Delphi Panel* (Abstract ID 9345) |
| | *VISION AD-JP: A Prospective Multicenter Real-world Study of Japanese Patients with Early Alzheimer's Disease Treated with Lecanemab* (Abstract ID 13235) |
| | *Real-World Outcomes with Lecanemab Treatment in a New England Alzheimer's Disease Center* (Abstract ID 1949) |
| | *Estimating the Economic Impact of Delayed Alzheimer's Disease Progression with Lecanemab* (Abstract ID 9889) |
| | *Economic, Health, and Quality-of-Life Burden on Caregivers and Study Partners of Lecanemab-Treated Individuals with Alzheimer's Disease* (Abstract ID 6169) |

**Eisai-Sponsored Symposium**
*Symposium is intended for HCPs only*

| Presentation date and time | Title |
|---|---|
| July 14<br>12:30 – 1:45pm | *Early Intervention in Alzheimer's Disease: Building the Evidence from Pathology to Practice* |

---

*The information was released for public disclosure, through the agency of the contact person below, on June 30, 2026, at 8am CET.*

**For further information, please contact:**
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180

Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08

**About Leqembi® (lecanemab)**
Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 8 countries, including the United Kingdom, China, the US and Japan, and applications have been filed in 12 countries and regions. In the US, Leqembi Iqlik™ is approved for subcutaneous dosing with an autoinjector for maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China. In January 2026, Eisai's supplemental Biologics License Application (sBLA) regarding a subcutaneous starting dose with Leqembi Iqlik was granted Priority Review by the US FDA. The sBLA has been assigned an extended PDUFA date of August 24, 2026. In January 2026, the Biologics License Application for subcutaneous formulation of Leqembi was accepted in China and in February, the application was designated for priority review.

Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in Alzheimer's disease and related dementias in the US, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

**About the collaboration between BioArctic and Eisai**
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody lecanemab back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.

**About BioArctic AB**
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.